Follow the evidence.
Original study papers and regulatory documents behind the comparisons. Each source lists its publication date and identifier.
In this guide
Original documents
Numbered citations in a comparison link to the relevant document below. A study of one peptide or population does not automatically support a claim about another.
9 documents, in the order the figures above use them. The date on each is the one printed on the document.
- Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues.Document date: 2003-09-26. PMID 14499707, doi:10.1016/s0169-409x(03)00109-1.
- Food and Drug Administration, Department of Health and Human Services. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.Document date: published 2013-03-04, signed 2013-02-26. 78 FR 14095, FR Doc. 2013-04827, Docket No. FDA-2012-P-1071.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475.
- Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use — full prescribing information.Document date: label face date: Revised 03/2024; label version published 2026-07-31. SPL set id 3d783378-b02d-4f19-99dd-0fc91a042224, Initial U.S. Approval 2010.
- Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use — full prescribing information.Document date: label face date: Revised 03/2025; label version published 2026-08-03. SPL set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, Initial U.S. Approval 2010.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.Document date: 2009-06. PMID 19289567, doi:10.1124/jpet.108.149211.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Document date: 1999-09. PMID 10496658, doi:10.1023/a:1018955126402.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue.Document date: 1998-11. PMID 9849822, doi:10.1530/eje.0.1390552.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Document date: 2006-03. PMID 16352683, doi:10.1210/jc.2005-1536.
Reading the evidence
Check the exact molecule, study population, intervention and outcome. Where a document reports a range, we retain both ends. Where a human measurement is not reported, we say so instead of supplying a number.
A label's date matters. Different editions may describe different products, populations or measurements. The source list identifies the document itself; an article's revision date does not mean every underlying study is new.
Our editorial policy explains how we separate evidence, provider information and commercial relationships.
Provider information is a different kind of source
Provider reviews describe public product and price information, not independently verified treatment outcomes or personal treatment experiences. Recorded offers retain their original medication, supply and billing terms; current offers may differ.
Read the provider reviews for those details, and confirm the current prescription, full cost and cancellation terms directly before paying.